Neutral
●
MarketBeat
●
vor 4 Monaten
Though the first GLP-1 agonists date back more than 20 years, it's only in the last couple of years that they began to dominate the pharmaceutical space for their massive potential as weight loss drugs. With some estimates placing the market at nearly $63 billion in early 2026, forecasts call for the GLP-1 industry to roughly triple over the coming decade.